Production (Stage)
Eledon Pharmaceuticals, Inc.
ELDN
$2.87
-$0.13-4.33%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 4.53M | 6.46M | 4.09M | 4.50M | 3.56M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 17.96M | 24.70M | 20.51M | 14.50M | 10.87M |
Operating Income | -17.96M | -24.70M | -20.51M | -14.50M | -10.87M |
Income Before Tax | -6.50M | -44.19M | 76.97M | -44.91M | -23.63M |
Income Tax Expenses | -- | 431.00K | -- | -- | -- |
Earnings from Continuing Operations | -6.50M | -44.62M | 76.97M | -44.91M | -23.63M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -6.50M | -44.62M | 76.97M | -44.91M | -23.63M |
EBIT | -17.96M | -24.70M | -20.51M | -14.50M | -10.87M |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | -0.08 | -0.60 | 1.05 | -0.60 | -0.79 |
Normalized Basic EPS | -0.05 | -0.40 | 0.93 | -0.66 | -0.49 |
EPS Diluted | -0.08 | -0.60 | -0.32 | -0.60 | -0.79 |
Normalized Diluted EPS | -0.05 | -0.40 | 0.87 | -0.66 | -0.49 |
Average Basic Shares Outstanding | 77.13M | 69.85M | 51.95M | 42.39M | 29.99M |
Average Diluted Shares Outstanding | 77.13M | 69.85M | 55.48M | 42.39M | 29.99M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |